Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Birch pollen extract - Stallergenes Greer plc

Next Previous
Drug Profile

Birch pollen extract - Stallergenes Greer plc

Alternative Names: Bet v 1; Bet v 1a; Oralair Bet V 1 recombinant allergen; Oralair Birch; rBet v 1; Staller (Birch); Staloral Birch; STALORAL® Birch 300 IR

Latest Information Update: 01 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stallergenes SA
  • Developer Endo International; Stallergenes Greer plc; Stallergenes SA
  • Class Allergens; Peptide vaccines; Peptides; Skin disorder therapies; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Seasonal allergic rhinitis

Most Recent Events

  • 25 May 2023 Phase-III clinical trials in Seasonal allergic rhinitis in European Union (Sublingual) (In children, In adolescents) (NCT05668390)
  • 03 Jan 2023 Stallergenes Greer plans a phase III trial for Allergic rhinoconjunctivitis (In Children, In adolescents) in October 2023 (NCT05668390)
  • 14 Sep 2022 Stallergenes initiates phase III trial for Seasonal allergic rhinitis (In children, In adolescents) in Austria, France and Sweden (Sublingual) (EudraCT2022-002012-23)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top